Using small molecules to enhance a virus treatment for melanoma
Official title: Harnessing the potential of pharmacological small molecules to amplify VSV-based oncolytic viral therapy
Funded at Southern Univ A&m Col Baton Rouge · NIH-10876187 · Data updated 2026-11-12
This study is looking at how certain small drugs can help a virus treatment work better for melanoma, a serious skin cancer, by making it easier for the virus to attack and kill cancer cells, which could lead to improved results for patients.
Quick facts
| Grant type | R15 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Southern Univ A&m Col Baton Rouge NIH-funded |
| Lab location | 1 site (Baton Rouge, United States) |
| Project start | July 5, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $408,966 |
| NIH project number | 1R15CA290568-01 |
| Project ID | NIH-10876187 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include patients diagnosed with malignant cutaneous melanoma who have limited treatment options.
✕Less likely to help
Patients with non-melanoma skin cancers or those who have already received extensive treatment may not benefit from this research.
What this research studies
This research investigates how small pharmacological molecules can improve the effectiveness of a virus-based therapy for melanoma, a deadly skin cancer. The approach focuses on inhibiting specific cellular pathways that cancer cells use to survive, allowing the oncolytic virus to better infect and kill these cancer cells. By studying this in a mouse model, the researchers aim to understand how to enhance the virus's ability to spread within tumors and induce cancer cell death, potentially leading to better treatment outcomes for patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for melanoma, improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in using oncolytic viruses for cancer treatment, suggesting that this approach could be a viable option for melanoma therapy.
Where this research is happening
-
Southern Univ A&m Col Baton Rouge
Baton Rouge, United States Active
Researchers
- Principal investigator: Chamcheu, Jean Christopher — Southern Univ A&m Col Baton Rouge
- Study coordinator: Chamcheu, Jean Christopher
Related research
Other NIH-funded projects on the same topics.
-
Understanding how Legionella bacteria cause disease
This study is looking at how the Legionella bacteria, which causes Legionnaires' disease, manages to dodge our immune system and cause infections, with the hope of finding new ways to prevent and treat the illness.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.